Amphastar Pharmaceuticals, Inc. (AMPH) Stock AnalysisAMPHAmphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amphastar Pharmaceuticals Inc is not a good buy right now due to several concerning factors. The current price is $26.62, but analysts have downgraded their price targets significantly, with BofA setting a target of $20, which represents a potential downside of about 25%. Additionally, insider selling has surged by 4073.82%, indicating a lack of confidence from those closest to the company. The recent FDA warning letter could also negatively impact the company's reputation and future sales.

6 analysts cover AMPH: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 32.00.